KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Net Margin (2017 - 2025)

Sarepta Therapeutics has reported Net Margin over the past 12 years, most recently at 63.86% for Q4 2025.

  • Quarterly results put Net Margin at 63.86% for Q4 2025, down 9042.0% from a year ago — trailing twelve months through Dec 2025 was 32.26% (down 4552.0% YoY), and the annual figure for FY2025 was 32.45%, down 4572.0%.
  • Net Margin for Q4 2025 was 63.86% at Sarepta Therapeutics, down from 45.06% in the prior quarter.
  • Over the last five years, Net Margin for SRPT hit a ceiling of 123.76% in Q4 2021 and a floor of 2348.35% in Q1 2023.
  • Median Net Margin over the past 5 years was 35.24% (2021), compared with a mean of 241.96%.
  • Biggest five-year swings in Net Margin: plummeted -229854bps in 2023 and later surged 235719bps in 2024.
  • Sarepta Therapeutics' Net Margin stood at 123.76% in 2021, then tumbled by -85bps to 18.29% in 2022, then tumbled by -77bps to 4.23% in 2023, then soared by 527bps to 26.56% in 2024, then crashed by -340bps to 63.86% in 2025.
  • The last three reported values for Net Margin were 63.86% (Q4 2025), 45.06% (Q3 2025), and 32.92% (Q2 2025) per Business Quant data.